• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biotechnology Progress >Designing anti-diabetic -cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis
【24h】

Designing anti-diabetic -cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis

机译：使用聚苯乙烯磺酸盐，聚烯丙胺和叔胆汁酸设计抗糖尿病细胞微胶囊：形态学，生物能学和细胞因子分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Recently sodium alginate (SA)-poly-l-ornithine (PLO) microcapsules containing pancreatic -cells that showed good morphology but low cell viability (<27%) was designed. In this study, two new polyelectrolytes, polystyrenic sulfonate (PSS; at 1%) and polyallylamine (PAA; at 2%) were incorporated into a microencapsulated-formulation, with the aim of enhancing the physical properties of the microcapsules. Following incorporation, the structural characteristics and cell viability were investigated. The effects of the anti-inflammatory bile acid, ursodeoxycholic acid (UDCA), on microcapsule morphology, size, and stability as well as -cell biological functionality was also examined. Methods: Microcapsules were prepared using PLO-PSS-PAA-SA mixture and two types of microcapsules were produced: without UDCA (control) and with UDCA (test). Microcapsule morphology, stability, and size were examined. Cell count, microencapsulation efficiency, cell bioenergetics, and activity were also examined. Results: The new microcapsules showed good morphology but cell viability remained low (29%+/- 3%). UDCA addition improved cell viability post-microencapsulation (42 +/- 5, P<0.01), reduced swelling (P<0.01), improved mechanical strength (P<0.01), increased Zeta-potential (P<0.01), and improved stability. UDCA addition also increased insulin production (P<0.01), bioenergetics (P<0.01), and decreased -cell TNF- (P<0.01), IFN-gamma (P<0.01), and IL-6 (P<0.01) secretions. Conclusions: Addition of 4% UDCA to a formulation system consisting of 1.8% SA, 1% PLO, 1% PSS, and 2% PAA enhanced cell viability post-microencapsulation and resulted in a more stable formulation with enhanced encapsulated -cell metabolism, bioenergetics, and biological activity with reduced inflammation. This suggests potential application of UDCA, when combined with SA, PLO, PSS, and PAA, in -cell microencapsulation and diabetes treatment. (c) 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:501-509, 2016
机译：目的：最近设计了含有胰腺细胞的藻酸钠（SA）-聚-1-鸟氨酸（PLO）微胶囊，该微胶囊具有良好的形态但细胞活力较低（<27％）。在这项研究中，两种新的聚电解质，聚苯乙烯磺酸盐（PSS; 1％）和聚烯丙胺（PAA; 2％）被掺入微胶囊化制剂中，目的是增强微胶囊的物理性能。掺入后，研究了结构特征和细胞活力。还检查了抗炎胆汁酸熊去氧胆酸（UDCA）对微胶囊形态，大小和稳定性以及-细胞生物学功能的影响。方法：使用PLO-PSS-PAA-SA混合物制备微囊，并生产两种类型的微囊：无UDCA（对照）和UDCA（测试）。检查了微胶囊的形态，稳定性和大小。还检查了细胞计数，微囊化效率，细胞生物能和活性。结果：新的微胶囊显示出良好的形态，但细胞活力仍然较低（29％+ /-3％）。添加UDCA可改善微囊化后的细胞活力（42 +/- 5，P <0.01），减少的溶胀（P <0.01），改善的机械强度（P <0.01），增强的Zeta电位（P <0.01）和改善的稳定性。添加UDCA还可以增加胰岛素产生（P <0.01），生物能学（P <0.01）和减少的细胞TNF-（P <0.01），IFN-γ（P <0.01）和IL-6（P <0.01）分泌。结论：在由1.8％SA，1％PLO，1％PSS和2％PAA组成的制剂体系中添加4％UDCA可以提高微囊化后的细胞活力，并导致更稳定的制剂，并具有增强的囊状细胞代谢，生物能学，并具有减少炎症的生物活性。这表明当与SA，PLO，PSS和PAA结合使用时，UDCA在细胞微囊化和糖尿病治疗中的潜在应用。 （c）2016美国化学工程师学会生物技术学会。 Prog。，32：501-509，2016

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号